SUNNYVALE, CA, Corsair Pharma, a private biopharmaceutical company, announced the closing of its $23M Series B financing led by New Rhein Healthcare Investors.
Corsair Pharma, Inc., a private biopharmaceutical company developing a transdermal treprostinil prodrug, announced the closing of its $23M Series B financing led by New Rhein Healthcare Investors.
Wedbush PacGrow functioned as a financial advisor to Corsair Pharma for the Series B financing. Junson Capital, Primavera Capital, Plaisance Capital and Midas Capital joined New Rhein as co-investors in this financing.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
